WO2011077711A1 - 新規な2-ピリドン誘導体及びこれを含有する医薬 - Google Patents
新規な2-ピリドン誘導体及びこれを含有する医薬 Download PDFInfo
- Publication number
- WO2011077711A1 WO2011077711A1 PCT/JP2010/007417 JP2010007417W WO2011077711A1 WO 2011077711 A1 WO2011077711 A1 WO 2011077711A1 JP 2010007417 W JP2010007417 W JP 2010007417W WO 2011077711 A1 WO2011077711 A1 WO 2011077711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- biphenyl
- butyl
- group
- oxo
- Prior art date
Links
- 0 C*(C=CC=C1)C=C1c1ccc(C)cc1 Chemical compound C*(C=CC=C1)C=C1c1ccc(C)cc1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a novel 2-pyridone derivative having an angiotensin II antagonism and PPAR ⁇ activation and a pharmaceutical containing the same.
- arteriosclerotic diseases such as diabetes, hypertension, dyslipidemia, obesity, etc.
- the number of diseases that can be risk factors is increasing rapidly. Although these diseases are independent risk factors, their duplication has been shown to cause more frequent onset and severity of arteriosclerotic diseases. Therefore, efforts are being made to understand the pathological condition that combines risk factors of multiple arteriosclerotic diseases with the concept of metabolic syndrome, and to elucidate the cause and develop treatment methods.
- Angiotensin II (hereinafter sometimes abbreviated as AII) is a peptide discovered as an endogenous pressor substance produced by the renin-angiotensin system (RA system). Pharmacological inhibition of angiotensin II is thought to lead to treatment or prevention of cardiovascular diseases such as hypertension, and inhibits angiotensin I (AI) to angiotensin II-converting enzyme as an inhibitor of RA.
- Angiotensin-converting enzyme (ACE) inhibitors have been used clinically.
- an AII receptor antagonist (Angiotensin Receptor Blocker: ARB) that can be administered orally has been developed, and losartan, candesartan, telmisartan, valsartan, olmesartan, irbesartan, and the like have been clinically used as antihypertensive agents.
- ARB is not only an antihypertensive effect, but also has various effects such as an anti-inflammatory effect, an endothelial function improving effect, a cardiovascular remodeling suppressing effect, an oxidative stress suppressing effect, a growth factor suppressing effect, and an insulin resistance improving effect.
- Non-patent Documents 1 and 2 Numerous reports have been reported in clinical or basic tests that it is useful for vascular diseases, renal diseases, arteriosclerosis, and the like. In particular, in recent years, an ARB renoprotective action that does not depend on an antihypertensive action has also been reported (Non-patent Document 3).
- PPARs peroxisome-proliferator-activated receptors belonging to the nuclear receptor superfamily have been identified so far as three isoforms of ⁇ , ⁇ and ⁇ .
- PPAR ⁇ is an isoform that is most expressed in adipose tissue and plays an important role in adipocyte differentiation and glycolipid metabolism.
- thiazolidinedione derivatives such as pioglitazone and rosiglitazone are clinically used as anti-diabetic drugs having PPAR ⁇ activation activity, and may exhibit an action to improve insulin resistance, glucose tolerance, lipid metabolism, etc. are known.
- TZD exhibits various actions such as an antihypertensive action, an anti-inflammatory action, an endothelial function improving action, a growth factor suppressing action, and an interference action with the RA system by the activation of PPAR ⁇ . Due to these multifaceted actions, it has been reported that TZD exhibits a renal protective action independent of blood glucose control, particularly in diabetic nephropathy (Non-Patent Documents 4, 5, 6, 7, and 8). However, on the other hand, TZD is feared for side effects such as fluid retention, weight gain, peripheral edema, and pulmonary edema induced by PPAR ⁇ operation (Non-Patent Documents 9 and 10).
- Non-patent Document 11 telmisartan has a PPAR ⁇ activation effect
- Non-patent Document 12 irbesartan has a similar effect
- Heart disease angina pectoris, cerebrovascular disorder, cerebral circulatory disorder, ischemic peripheral circulatory disorder, kidney disease, etc.
- diabetes related diseases type 2 diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, high It is expected as an integrated preventive and / or therapeutic agent for insulinemia and the like (Patent Document 1).
- a synergistic preventive and / or therapeutic effect can be expected by a combined renal protective action by RA system inhibition and PPAR ⁇ activation action.
- Patent Document 1 pyrimidine and triazine derivatives
- Patent Document 2 imidazopyridine derivatives
- Patent Document 3 indole derivatives
- Patent Document 4 imidazole derivatives
- Patent Document 5 fused ring derivatives
- Patent Document 1 discloses the following formula (A):
- R 1 represents an oxygen atom, a sulfur atom or the like
- R 2 represents the following formula (Ad):
- R 6 represents a group represented by the above formula (Ae), Z represents an oxygen atom, S (O) n , n represents an integer of 0 to 2, Y represents C 1 -C 4 R 3 and R 4 each independently represent a hydrogen atom, a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, a C 1 -C 6 alkoxy group, a C 1 -C 6 shows an alkylamino group such as a group selected from, R 5 represents a hydrogen atom, C 1 -C 6 alkyl, a group selected from C 2 -C 6 alkenyl group.
- the compound represented by this is disclosed.
- the heterocyclic moiety in the document is of formula (Aa) to formula (Ac) and is different from the 2-pyridone skeleton of the present invention.
- Patent Document 6 the following formula (B):
- ring A represents an aromatic heterocyclic group having 5 to 10 ring atoms which may further have a substituent other than R 1 and R 2 , and R 1 is bonded via a hetero atom.
- An optionally substituted hydrocarbon residue R 2 represents a group capable of releasing a proton in vivo or a group capable of being converted to this, and R 3 represents a carbonyl group, thio group as a ring-constituting group.
- X represents ring Y and ring W directly or atoms
- the ring W and the ring Y each represents an optionally substituted aromatic hydrocarbon or aromatic heterocyclic residue, and
- n represents an integer of 1 to 3. Show. The compound represented by this is disclosed. However, there is no description or suggestion about the pharmacological activity of the PPAR ⁇ activating action and the treatment of diabetes, obesity or metabolic syndrome for the compounds in the literature.
- R 2 has a proton-releasing substituent such as a carboxyl group, a tetrazolyl group, a trifluoromethanesulfonic acid amide group, a phosphoric acid group or a sulfonic acid group.
- Patent Document 7 discloses the following formula (C):
- R 1 , R 2 , R 3 and R 4 represent hydrogen, lower alkyl group, lower alkenyl group, hydroxymethyl group, hydroxy group, carboxymethyl group, nitro group, methoxy group, sulfonylamino group or halogen, respectively.
- R 5 represents a carboxy group or a tetrazole group. The compound represented by this is reported. However, there is no description or suggestion about the pharmacological activity of the PPAR ⁇ activating action and the treatment of diabetes, obesity or metabolic syndrome for the compounds in the literature. Moreover, it is different from the compound of the present invention in that it does not have a substituent on the nitrogen atom of the pyridine ring.
- An object of the present invention is to provide a novel compound useful as a medicament for prevention and / or treatment of hypertension which is a circulatory system disease and diabetes which is a metabolic disease, and a pharmaceutical composition using the same. It is in.
- the 2-pyridone derivative represented by the general formula (1) is a compound having both an excellent angiotensin II antagonism and PPAR ⁇ activation. As a result, the present invention was reached.
- R 1 represents a C 1-6 alkyl group or a C 1-6 alkoxy group
- R 2 represents a C 1-6 alkyl group or a C 3-8 cycloalkyl group
- R 3 represents a C 1-6 alkyl group, a C 6-10 aryl-C 1-6 alkyl group, a C 1-6 alkoxy-C 1-6 alkyl group, or the following formula (2):
- R 4 represents the following formula (3) or (4):
- the compound represented by the general formula (1) is: 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -1-benzyl-4-butyl-6-methylpyridin-2 (1H) -one, 3- ⁇ 4 '-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-yl ⁇ -1,2,4-oxa Diazol-5 (4H) -one, 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -1-benzyl-6-methyl-4-propylpyridin-2 (1H) -one, 3- ⁇ 4 '-[(1-Benzyl-6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-yl ⁇
- a pharmaceutical composition comprising the compound according to any one of [1] or [2] or a salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition having both an angiotensin II receptor antagonistic action and a PPAR ⁇ activation action comprising as an active ingredient the compound according to any one of [1] or [2] above, or a salt thereof, or a solvate thereof. .
- a preventive and / or therapeutic agent for cardiovascular disease comprising the compound or salt thereof according to any one of [1] or [2] above or a solvate thereof as an active ingredient.
- cardiovascular disease is hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulation disorder, ischemic peripheral circulation disorder, renal disease or arteriosclerosis. / Or therapeutic agent.
- a preventive and / or therapeutic agent for a metabolic disease comprising the compound or salt thereof according to any one of [1] or [2] above, or a solvate thereof as an active ingredient.
- the metabolic disease is type 2 diabetes, diabetic complications (diabetic retinopathy, diabetic neuropathy or diabetic nephropathy), insulin resistance syndrome, metabolic syndrome or hyperinsulinemia [7]
- the preventive and / or therapeutic agent according to 1.
- a circulatory system characterized by administering to a patient in need of treatment an effective amount of the compound or a salt thereof according to any of [1] or [2] above, or a solvate thereof.
- a method for preventing and / or treating a disease characterized by administering to a patient in need of treatment an effective amount of the compound or a salt thereof according to any of [1] or [2] above, or a solvate thereof.
- a metabolic disease characterized by administering to a patient in need of treatment an effective amount of a compound or salt thereof, or a solvate thereof according to either [1] or [2] above Prevention and / or treatment method.
- the 2-pyridone derivative represented by the general formula (1) of the present invention or a salt thereof, or a solvate thereof exhibits a strong antagonistic action on the angiotensin II receptor and is associated with diseases involving angiotensin II such as hypertension.
- the 2-pyridone derivative represented by the general formula (1) of the present invention or a salt thereof, or a solvate thereof exhibits a PPAR ⁇ activation action, and is a disease involving PPAR ⁇ , such as arteriosclerosis, 2 And / or therapeutic agents for metabolic diseases such as type 2 diabetes, diabetic complications (diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), insulin resistance syndrome, syndrome X, metabolic syndrome, hyperinsulinemia It can be suitably used as an active ingredient.
- a disease involving PPAR ⁇ such as arteriosclerosis, 2 And / or therapeutic agents for metabolic diseases such as type 2 diabetes, diabetic complications (diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), insulin resistance syndrome, syndrome X, metabolic syndrome, hyperinsulinemia It can be suitably used as an active ingredient.
- the 2-pyridone derivative represented by the general formula (1) of the present invention or a salt thereof, or a solvate thereof has both an angiotensin II receptor antagonistic action and a PPAR ⁇ activation action, and angiotensin II and PPAR ⁇ It can be suitably used as an active ingredient of a preventive and / or therapeutic agent for diseases involving both, for example, arteriosclerosis, diabetic nephropathy, insulin resistance syndrome, syndrome X, and metabolic syndrome.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- C 1-6 alkyl group and “C 1-6 alkyl” mean a linear or branched hydrocarbon group having 1 to 6 carbon atoms, such as a methyl group.
- C 1-6 alkoxy group and “C 1-6 alkoxy” mean a linear or branched alkoxy group having 1 to 6 carbon atoms, such as a methoxy group Ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentoxy group, isopentoxy group, neopentoxy group, hexyloxy group or isohexyloxy group.
- C 3-8 cycloalkyl group means a saturated or unsaturated monocyclic, polycyclic or fused cyclic group having 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms.
- a cycloalkyl group examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentyl group, a cyclooctyl group, and the like.
- C 1-6 alkoxy-C 1-6 alkyl group means a C 1-6 alkyl group substituted with 1 to 3 C 1-6 alkoxy. Specifically, for example, methoxymethyl group, methoxyethyl group, methoxypropyl group, ethoxymethyl group, ethoxyethyl group, propoxymethyl group, propoxyethyl group, butoxymethyl group, butoxyethyl group, 2,2-dimethoxyethyl group Etc.
- C 6-10 aryl includes monocyclic or condensed cyclic carbocyclic aryl groups having 6 to 10 carbon atoms. Examples of such an aryl group include a phenyl group, a naphthyl group, and an azulenyl group.
- C 6-10 aryl-C 1-6 alkyl group means a C 1-6 alkyl group substituted with the C 6-10 aryl. Specific examples include a benzyl group, a phenethyl group, a phenylpropyl group, a phenylbutyl group, a phenylpentyl group, a phenylhexyl group, a naphthylmethyl group, and an azulenylmethyl group.
- the C 1-6 alkyl group in R 1 is preferably a C 3-5 alkyl group, for example, an n-propyl group, an n-butyl group, or an n-pentyl group.
- the C 1-6 alkoxy group in R 1 is preferably a C 2-5 alkyl group, for example, an n-propoxy group.
- the C 1-6 alkyl group in R 2 is preferably a C 1-4 alkyl group, for example, a methyl group.
- the C 3-8 cycloalkyl group in R 2 is preferably C 3-6 cycloalkyl, for example, a cyclopropyl group, a cyclobutyl group, or a cyclopentyl group.
- the C 1-6 alkyl group in R 3 is preferably a C 1-4 alkyl group, for example, a methyl group or an ethyl group is preferable.
- the “C 6-10 aryl-C 1-6 alkyl group” in R 3 is preferably “C 6-10 aryl-C 1-4 alkyl group”, for example, benzyl group, phenethyl Groups are preferred.
- the “C 1-6 alkoxy-C 1-6 alkyl group” in R 3 is preferably a “C 1-4 alkoxy-C 1-4 alkyl group”, for example, a methoxyethyl group preferable.
- the C 1-6 alkoxy group in R 5 is preferably a C 1-4 alkoxy group, for example, a methoxy group or an ethoxy group.
- R 5 may be substituted at any of the 4, 5, and 6 positions, but is preferably at the 5 position.
- the salt of the compound represented by the general formula (1) is not particularly limited as long as it is a pharmaceutically acceptable salt.
- alkali metal salt or alkaline earth metal salt such as sodium, potassium, magnesium, calcium
- acid addition salts of mineral acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate; benzoate
- examples include acid addition salts of organic acids such as methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, maleate, fumarate, tartrate, citrate, and acetate. It is done.
- Examples of the solvate of the compound represented by the general formula (1) or a salt thereof include, but are not limited to, hydrates and the like.
- prodrugs are also included in the present invention.
- examples of the group that forms a prodrug of the compound of the present invention include the groups described in “Progress in Medicine”, Life Science Medica, 1985, Vol. 5, pages 2157-2161. Examples include the groups described in Yodogawa Shoten, 1990, “Development of Drugs”, Vol.
- the compound represented by the above general formula (1) or a salt thereof, or a solvate thereof may be produced by various known methods. There is no particular limitation, and for example, it can be produced according to the reaction step described below. Moreover, when performing the following reaction, functional groups other than the reaction site may be protected in advance as necessary, and may be deprotected at an appropriate stage. The protection and deprotection conditions can be carried out with reference to commonly used methods (Protective Groups in Organic Synthesis Third Edition, John Wiley & Sons, Inc.). Further, in each step, the reaction may be carried out by a commonly performed method, and isolation and purification may be carried out by appropriately selecting or combining conventional methods such as crystallization, recrystallization, chromatography and the like.
- the compound (1a) in which R 4 is a tetrazolyl group can be produced by reacting the nitrile derivative (5) with an azide compound.
- the compound (1b) in which R 4 is a 5-oxo-1,2,4-oxadiazolyl group is obtained by reacting the nitrile derivative (5) with hydroxylamine to obtain an amide oxime form (6), and then an amide oxime form. It can be produced by reacting (6) with a carbonyl reagent.
- This reaction path is represented by the chemical reaction formula as follows. [Reaction Path Diagram 1]
- Step 1 The reaction of the nitrile derivative (5) and the azide compound can be carried out in a solvent.
- the azide compound trimethyltin azide, tributyltin azide, triphenyltin azide, sodium azide, hydrazoic acid or the like can be used. Trimethylsilyl azide may be used in the presence of dibutyltin oxide.
- the solvent is not particularly limited, but methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, toluene, benzene, dioxane, tetrahydrofuran, acetonitrile, propionitrile, N, N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide Etc. can be used alone or in combination. While the reaction conditions vary depending on the starting materials used, compound (1a) can be obtained by reacting at 0 to 180 ° C., preferably 50 to 120 ° C. for 1 minute to 2 weeks, preferably 1 hour to 3 days. .
- Step 2 The reaction of nitrile derivative (5) and hydroxylamine can be carried out in a solvent.
- the solvent is not particularly limited, but N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, methanol, ethanol, isopropanol, 1,4-dioxane, tetrahydrohyran, etc. are used alone or in combination. Can be used.
- a suitable base such as potassium carbonate, sodium bicarbonate, sodium hydroxide, triethylamine, sodium methoxide, Sodium hydride and the like can be reacted in an equivalent amount or in a slight excess.
- the reaction conditions vary depending on the raw materials used, but in general, the amide oxime derivative (6) is reacted at 0 to 180 ° C., preferably 50 to 120 ° C. for 1 minute to 3 days, preferably 1 hour to 36 hours. can get.
- Step 3 Conversion of the amide oxime derivative (6) to the compound (1b) can be carried out by using a carbonyl reagent in a solvent in the presence of a base.
- the solvent is not particularly limited, but 1,2-dichloroethane, chloroform, dichloromethane, ethyl acetate, isopropyl acetate, toluene, benzene, tetrahydrofuran, dioxane, acetonitrile, propionitrile, N, N-dimethylformamide, N, N— Dimethylacetamide, N-methylpyrrolidone, diethyl ether and the like can be used alone or in combination.
- the base is not particularly limited.
- pyridine, N, N-4-dimethylaminopyridine collidine, lutidine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) 1,5-diazabicyclo [3.4.0] non-7-ene (DBN), 1,4-diazabicyclo [2.2.2] octane (DABCO), triethylamine, N, N-diisopropylethylamine, diisopropylpentyl Amine, trimethylamine, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate and the like can be used.
- DMAP 1,8-diazabicyclo [5.4.0] undec-7-ene
- DBN 1,5-diazabicyclo [3.4.0] non-7-ene
- DABCO 1,4-diazabicyclo [2.2.2] octane
- triethylamine N, N-diisopropyleth
- the carbonyl reagent is not particularly limited, and 1,1'-carbonyldiimidazole, triphosgene, methyl chlorocarbonate, ethyl chlorocarbonate and the like can be used. While the reaction conditions vary depending on the raw materials used, compound (1b) is generally obtained by reacting at 0 to 120 ° C., preferably 15 to 80 ° C., for 5 minutes to 3 days, preferably 1 to 12 hours. .
- R 1 , R 2 and R 3 are the same as described above, X 1 and X 2 represent a leaving group such as a halogen atom or a sulfonyloxy group, and X 3 represents a halogen atom. .
- Step 4 This step can be produced with reference to a known method described in Richard H. et al., J.Amer.Chem.Soc., 2393-2398 (1956) and the like. That is, the 2-pyrone derivative (7) and the amine derivative (8) may be reacted in a solvent under superheating.
- the solvent is not particularly limited, but dichloromethane, 1,2-dichloroethane, chloroform, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, methanol, ethanol, isopropanol, 1,4 -Dioxane, tetrahydrohyran, water and the like can be used alone or in combination.
- the reaction conditions vary depending on the raw materials used, but the 2-pyridone derivative (9) is generally reacted at 50 to 150 ° C., preferably 80 to 120 ° C. for 5 minutes to 3 days, preferably 1 hour to 2 days. Is obtained.
- Step 5 The reaction of 2-pyridone derivative (9) and compound (10) can be carried out in a solvent in the presence of a base.
- Compound (10) can be produced by the method described in Devid J.Carini et al., J.Med.Chem., 34, 2525-2547 (1991) and the like.
- the solvent used in this step is not particularly limited, but N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, methanol, ethanol, isopropanol, 1,4-dioxane, tetrahydrohydrane, etc. Can be used alone or in combination.
- the base is not particularly limited.
- pyridine, DMAP, collidine, lutidine, DBU, DBN, DABCO, triethylamine, N, N-diisopropylethylamine, diisopropylpentylamine, triisopropylamine, lithium carbonate, sodium carbonate, potassium carbonate, carbonate Cesium, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium hydride, potassium hydride and the like can be used. While the reaction conditions vary depending on the starting materials used, compound (11) can be obtained by reacting at 0 to 120 ° C., preferably 50 to 120 ° C., for 5 minutes to 3 days, preferably 1 hour to 2 days. . In order to avoid side reactions, lithium halides such as lithium chloride may be added to this reaction.
- This step is a step for producing compound (12) by converting the hydroxyl group of compound (11) to a leaving functional group such as halogen or sulfonyloxy, and is carried out in a solvent in the presence of a base.
- Conversion from a hydroxyl group to a halogen atom may be performed using a halogenating agent in a solvent.
- the halogenating agent include phosphorus trichloride, phosphorus pentachloride, phosphorus tribromide, phosphorus oxychloride, phosphorus oxybromide and the like.
- dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, benzene, toluene, xylene, ethyl acetate, acetonitrile, propionitrile, N, N-dimethylformamide and the like can be used alone or in combination.
- organic bases such as pyridine, triethylamine, N, N-diisopropylethylamine may be added as a catalyst. Reaction conditions are -80 to 180 ° C., preferably 0 to 100 ° C.
- Conversion of the hydroxyl group to the sulfonyloxy group may be achieved, for example, by reacting the compound (11) with a sulfonic acid anhydride or a sulfonic acid halide in the presence of a base.
- the solvent for example, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, benzene, toluene, xylene, ethyl acetate, acetonitrile, propionitrile, N, N-dimethylformamide and the like can be used alone or in combination.
- the sulfonic acid anhydride include methanesulfonic acid anhydride, benzenesulfonic acid anhydride, trifluoromethanesulfonic acid anhydride, and the like.
- Examples of the sulfonic acid halide include methanesulfonic acid chloride, p-toluenesulfonic acid chloride, and the like. It is done.
- Examples of the base include organic bases such as pyridine, triethylamine and N, N-diisopropylethylamine, and inorganic bases such as potassium hydrogen carbonate, sodium hydrogen carbonate, potassium carbonate, sodium carbonate and calcium carbonate.
- the reaction conditions vary depending on the raw materials used, but by reacting at ⁇ 80 to 180 ° C., preferably 0 to 100 ° C. for 1 minute to 3 days, preferably 30 minutes to 24 hours, X 2 is a sulfonyloxy group. A certain compound (12) is obtained.
- Step 7 The reaction of compound (12) and organozinc compound (13) can be carried out in a solvent in the presence of a catalyst.
- a catalyst benzene, toluene, xylene, diethyl ether, tetrahydrofuran, dimethoxyethane, dioxane, acetonitrile, N, N-dimethylformamide, N-methylpiperidone, methanol, ethanol, water and the like can be used alone or in combination.
- Catalysts include tetrakis (triphenylphosphine) palladium (0), tris (bisbenzylideneacetone) dipalladium (0), palladium (II) acetate, palladium (II) chloride, dichloro [1,2-bis (diphenylphosphino). ) Ethane] palladium (II), dichloro [1,2-bis (diphenylphosphino) butane] palladium (II), dichloro [1,1′-bis (diphenylphosphino) ferrocene] palladium (II), etc. .
- a ligand such as -1,1′-binaphthyl and 1,2-bis (diphenylphosphino) ethane may be combined. While the reaction conditions vary depending on the raw materials used, compound (5) can be obtained by reacting at 20 to 180 ° C., preferably 20 to 100 ° C. for 1 minute to 3 days, preferably 1 hour to 24 hours.
- Step 8 the method described in Tetsuzo Kato et al. Chem.Pharm.Bull., 20 (1), 133-141 (1972) or a similar method may be used. That is, the reaction of diketene (14) and amine derivative (8) can be performed in a solvent under superheat.
- the solvent dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, benzene, toluene, xylene, ethyl acetate, acetonitrile, propionitrile, N, N-dimethylformamide, acetic acid and the like can be used alone or in combination. While the reaction conditions vary depending on the starting materials used, compound (15) can be obtained by reacting at 50 to 180 ° C., preferably 60 to 120 ° C. for 1 minute to 48 hours, preferably 10 minutes to 24 hours.
- the 2-pyridone derivative (9) can be produced by reacting the compound (15) with heating in the presence of an acid.
- an acid for example, hydrochloric acid, sulfuric acid, nitric acid or the like may be used as a solvent and reagent.
- the reaction conditions vary depending on the raw materials used, but the 2-pyridone derivative (9) can be obtained by reacting at 50 to 180 ° C., preferably 60 to 150 ° C. for 1 minute to 12 hours, preferably 1 minute to 6 hours. can get.
- Step 10 This step is a step for producing compound (16) by reacting 2-pyrone derivative (7) with compound (10) in a solvent in the presence of a base.
- the reaction may be performed using a method.
- Step 11 This step is a step of producing compound (17) by converting the hydroxyl group of compound (16) to a leaving functional group such as halogen or sulfonyloxy, etc., using the method of step 6 described above. A reaction may be performed.
- Step 12 This step is a step for producing compound (18) by reacting compound (17) with organozinc compound (13) in the presence of a catalyst in a solvent.
- the reaction may be performed using
- Step 13 This step is a step in which compound (18) and amine derivative (8) are reacted in a solvent under heating to produce intermediate (5), using the method of step 4 described above. A reaction may be performed.
- R 1 , R 2 and R 3 are the same as described above, R 1 ′ represents a C 1-6 alkyl group, and X 4 represents a halogen atom, a sulfonyloxy group, a hydroxyl group or the like. Indicates a leaving group.
- Step 14 When compound (19) in which X 4 is a halogen atom or a sulfonyloxy group is used, it can be carried out in a solvent in the presence of a base according to a commonly used technique for alkylating hydroxyl groups. .
- a solvent for example, chloroform, dichloromethane, tetrahydrofuran, toluene, dioxane, methanol, ethanol, ethyl acetate, acetonitrile, propionitrile, water and the like can be used alone or in combination.
- Examples of the base include pyridine, triethylamine, N, N-diisopropylethylamine, potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like.
- the reaction conditions are -80 to 180 ° C, preferably -30 to 130 ° C for 1 minute to 5 days, preferably 15 minutes to 3 days.
- the compound (11) and the compound (19) Compound (5 ′) can also be produced by reacting in a solvent in the presence of a phosphine reagent and an azo reagent.
- phosphine reagent for example, trialkylphosphine such as trimethylphosphine, triethylphosphine, tripropylphosphine, triisopropylphosphine, tributylphosphine, triisobutylphosphine, tricyclohexylphosphine and the like, and triarylphosphine such as triphenylphosphine are used. be able to.
- trialkylphosphine such as trimethylphosphine, triethylphosphine, tripropylphosphine, triisopropylphosphine, tributylphosphine, triisobutylphosphine, tricyclohexylphosphine and the like
- triarylphosphine such as triphenylphosphine
- the azo reagent is not particularly limited, but diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), di-tert-butyl azodicarboxylate (DBAD), 1,1- (azodicarbonyl) piperidine (ADDP) ), 1,1′-azobis (N, N′-diisopropylformamide) (TIPA), 1,6-dimethyl-1,5,7-hexahydro-1,4,6-tetrazocine-2,5-dione (DHAD) ) Etc.
- DEAD diethyl azodicarboxylate
- DIAD diisopropyl azodicarboxylate
- DBAD di-tert-butyl azodicarboxylate
- TIPA 1,1′-azobis (N, N′-diisopropylformamide)
- DHAD 1,6-dimethyl-1,5,7-hexahydro-1,4,
- ethylenedicarboxylic acid reagent for example, dimethyl maleate, diethyl maleate, dimethyl fumarate, diethyl fumarate and the like can be used.
- solvent for example, dichloromethane, chloroform, tetrahydrofuran, diethyl ether, dioxane, benzene, toluene, xylene, methanol, ethanol, N, N-dimethylformamide and the like can be used alone or in combination.
- the reaction conditions are -80 to 100 ° C, preferably -30 to 60 ° C for 1 minute to 5 days, preferably 15 minutes to 1 day.
- various isomers can be isolated by applying a conventional method using the difference in physicochemical properties between isomers.
- the racemic mixture is optically pure by a general racemic resolution method such as a method of optical resolution by introducing a diastereomeric salt with a general optically active acid such as tartaric acid or a method using optically active column chromatography. Can lead to isomers.
- a diastereomeric mixture can be divided
- An optically active compound can also be produced by using an appropriate optically active raw material.
- the obtained compound (1) can be converted into a salt by an ordinary method. Moreover, it can also be set as the solvate and hydrate of solvents, such as a reaction solvent and a recrystallization solvent. *
- Examples of the dosage form of a medicament comprising the compound of the present invention or a salt thereof, or a solvate thereof as an active ingredient include oral administration or intravenous administration such as tablets, capsules, granules, powders, syrups, etc.
- Examples include parenteral administration such as injections, intramuscular injections, suppositories, inhalants, transdermal absorption agents, eye drops, and nasal drops.
- this active ingredient can be used alone or in other pharmaceutically acceptable carriers, that is, excipients, binders, extenders, disintegrants, Surfactants, lubricants, dispersants, buffers, preservatives, flavoring agents, fragrances, coating agents, diluents and the like can be appropriately combined to prepare a pharmaceutical composition.
- the dosage of the medicament of the present invention varies depending on the patient's weight, age, sex, symptoms, etc., but in the case of a normal adult, it is usually 0.1 to 1000 mg, particularly 1 to 1 mg as a compound represented by the general formula (1). 300 mg can be administered orally or parenterally in one or several divided doses.
- Step 1 To a solution of 4-hydroxy-6-methyl-2-pyrone (3.8 g, 30 mmol) in water (20 mL) was added benzylamine (3.3 mL, 30 mmol) at room temperature, and the mixture was stirred overnight with heating under reflux. After allowing to cool to room temperature, the precipitated solid was collected by filtration to obtain 1-benzyl-4-hydroxy-6-methylpyridin-2 (1H) -one (3.7 g, 57%) as a pale yellow solid.
- Step 2 Lithium chloride (212 mg, 5 mmol) in a solution of 1-benzyl-4-hydroxy-6-methylpyridin-2 (1H) -one (1.1 g, 5 mmol) in N, N-dimethylformamide (30 mL) at room temperature , N, N-diisopropylethylamine (1.7 mL, 10 mmol), 4′-bromomethyl-2-cyanobiphenyl (1.6 g, 6 mmol) was added, and the mixture was stirred at 70 ° C. overnight. Water was added and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 3 of 4 ′-[(1-Benzyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile (540 mg, 1.3 mmol)
- pyridine 377 ⁇ L, 4.8 mmol
- trifluoromethanesulfonic anhydride 669 ⁇ L, 4.0 mmol
- Water was added and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 4 Preparation of 4 ′-[(1-benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile (18 mg, 0.040 mmol) Trimethylsilyl azide (264 ⁇ L, 2.0 mmol) and dibutyltin oxide (5 mg, 0.020 mmol) were added to a toluene (1.5 mL) solution, and the mixture was heated to reflux for 16 hours under an argon atmosphere.
- Step 1 Sodium hydrogen carbonate (948 mg, 11.29 mmol) was added to a dimethylsulfoxide solution (5 mL) of hydroxylamine hydrochloride (654 mg, 9.40 mmol), and the mixture was stirred at 40 ° C. for 1 hour. 4 ′-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbohydrate obtained in Step 3 of Example 1 was added to the reaction solution. A dimethyl sulfoxide solution (3 mL) of nitrile (168 mg, 0.38 mmol) was added and stirred at 90 ° C. for 16 hours.
- Step 2 To a N, N-dimethylformamide solution (1.5 mL) of the obtained pale yellow oily substance, 1,1-carbonyldiimidazole (114 mg, 0.70 mmol), 1,8-diazabicyclo [5.4.0] Undec-7-ene (105 ⁇ L, 0.70 mmol) was added and stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 1 Reaction and treatment were conducted in the same manner as in Step 3 of Example 1 using n-propyl zinc bromide instead of n-butyl zinc bromide, and 4 ′-[(1-benzyl-6-methyl-2-oxo- 4-Propyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was obtained.
- Step 2 4 ′-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile instead of 4 ′-[( 1-Benzyl-6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was reacted and treated in the same manner as in Step 4 of Example 1. 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -1-benzyl-6-methyl-4-propylpyridin-2 (1H) -one was obtained.
- Step 4 of Example 2 using 4 ′-[(1-benzyl-6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile 2- ⁇ 4 '-[(1-benzyl-6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-yl ⁇ -1,2,4-oxadiazol-5 (4H) -one was obtained.
- Step 1 Reaction and treatment were carried out in the same manner as in Step 3 of Example 1 using n-pentyl zinc bromide instead of n-butyl zinc bromide, and 4 ′-[(1-benzyl-6-methyl-2-oxo- 4-Pentyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was obtained.
- Step 2 4 ′-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile instead of 4 ′-[( 1-Benzyl-6-methyl-2-oxo-4-pentyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was reacted and treated in the same manner as in Step 4 of Example 1. 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -1-benzyl-6-methyl-4-pentylpyridin-2 (1H) -one was obtained.
- Step 1 of Example 5 instead of 4 ′-[(1-benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile
- Step 4 of Example 2 using 4 ′-[(1-benzyl-6-methyl-2-oxo-4-pentyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile 2- ⁇ 4 '-[(1-benzyl-6-methyl-2-oxo-4-pentyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-yl ⁇ -1,2,4-oxadiazol-5 (4H) -one was obtained.
- Step 1 Reaction and treatment are conducted in the same manner as in Step 1 of Example 1 using 2-phenylethylamine instead of benzylamine to obtain 4-hydroxy-6-methyl-1-phenethylpyridin-2 (1H) -one. It was.
- Step 2 Example 1 using 4-hydroxy-6-methyl-1-phenethylpyridin-2 (1H) -one instead of 1-benzyl-4-hydroxy-6-methylpyridin-2 (1H) -one 4 ′-[(4-Hydroxy-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was reacted and treated in the same manner as in Step 2. Got.
- Step 3 4 ′-[(1-Benzyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile instead of 4 ′-[( 4-hydroxy-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was used for the reaction and treatment in the same manner as in Step 3 of Example 1. 4 ′-[(4-Butyl-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was obtained.
- Step 4 4 ′-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile instead of 4 ′-[( 4-Butyl-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was used for the same reaction and treatment as in Step 4 of Example 1. 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -4-butyl-6-methyl-1-phenethylpyridin-2 (1H) -one was obtained.
- Step 3 of Example 7 Obtained in Step 3 of Example 7 instead of 4 ′-[(1-benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile 4 ′-[(4-Butyl-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile was used, step 1 of Example 2, 2- ⁇ 4 '-[(4-Butyl-6-methyl-2-oxo-1-phenethyl-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-yl ⁇ -1,2,4-oxadiazol-5 (4H) -one was obtained.
- Step 1 Reaction and treatment were conducted in the same manner as in Step 1 of Example 1 using 2-methoxyethylamine instead of benzylamine to give 4-hydroxy-1- (2-methoxyethyl) -6-methylpyridine-2 (1H ) -One was obtained.
- Step 2 Instead of 1-benzyl-4-hydroxy-6-methylpyridin-2 (1H) -one, 4-hydroxy-1- (2-methoxyethyl) -6-methylpyridin-2 (1H) -one Using 4 ′- ⁇ [4-hydroxy-1- (2-methoxyethyl) -6-methyl-2-oxo-1,2-dihydropyridine-3- [Il] methyl ⁇ biphenyl-2-carbonitrile was obtained.
- Step 3 Instead of 4 ′-[(1-benzyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile, 4 ′- ⁇ [ Similar to Step 3 of Example 1 using 4-hydroxy-1- (2-methoxyethyl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbonitrile 4 ′- ⁇ [4-butyl-1- (2-methoxyethyl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile Got.
- Step 4 4 ′-[(1-Benzyl-4-butyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile instead of 4 ′- ⁇ [ Similar to Step 4 of Example 1 using 4-butyl-1- (2-methoxyethyl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbonitrile 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -4-butyl-1- (2-methoxyethyl) -6-methylpyridine-2 (1H) -one was obtained.
- Step 1 Diketene (2.8 mL, 36 mmol) and triethylamine (2 mL, 14 mmol) were added to a toluene (30 mL) solution of 2-amino-5-ethoxypyrimidine (1.4 g, 10 mmol), and the mixture was stirred at 85 ° C. for 24 hours. After the solvent was distilled off, ethyl acetate (10 mL) was added and heated to reflux for 30 minutes. Allow to cool to room temperature and filter the solution to 3-acetyl-1- (5-ethoxypyrimidin-2-yl) -4-hydroxy-6-methylpyridin-2 (1H) -one (1.10 g, 38%) Was obtained as a black solid.
- Step 3 1- (5-Ethoxypyrimidin-2-yl) -4-hydroxy-6-methylpyridin-2 (1H) -one (240 mg, 0.97 mmol) in N, N-dimethylformamide (5 mL) solution Lithium chloride (41 mg, 0.97 mmol), N, N-diisopropylethylamine (338 ⁇ L, 1.9 mmol), 4′-bromomethyl-2-cyanobiphenyl (238 mg, 0.87 mmol) were added at room temperature, and the mixture was stirred at 70 ° C. overnight. did. Water was added and extracted with ethyl acetate.
- Step 4 4 ′- ⁇ [1- (5-Ethoxypyrimidin-2-yl) -4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbo
- nitrile 80 mg, 0.18 mmol
- dichloromethane 3.0 mL
- pyridine 52 mg, 0.66 mmol
- trifluoromethanesulfonic anhydride 92 ⁇ L, 0.55 mmol
- Step 5 4 ′- ⁇ [4-Butyl-1- (5-ethoxypyrimidin-2-yl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbo
- Trimethylsilyl azide (230 ⁇ L, 1.8 mmol) and dibutyltin oxide (4 mg, 0.018 mmol) were added to a solution of nitrile (18 mg, 0.035 mmol) in toluene (1.5 mL), and the mixture was heated to reflux for 16 hours under an argon atmosphere.
- Step 1 Sodium hydrogen carbonate (320 mg, 3.8 mmol) was added to a dimethylsulfoxide solution (4 mL) of hydroxylamine hydrochloride (221 mg, 3.2 mmol), and the mixture was stirred at 40 ° C. for 1 hour.
- 4 ′- ⁇ [4-butyl-1- (5-ethoxypyrimidin-2-yl) -6-methyl-2-oxo-1,2-dihydropyridine-3-] obtained in Step 4 of Example 11 was used.
- [Il] methyl ⁇ biphenyl-2-carbonitrile (65 mg, 0.13 mmol) in dimethyl sulfoxide (2 mL) was added, and the mixture was stirred at 90 ° C. for 16 hr.
- Step 2 To the N, N-dimethylformamide solution (1.5 mL) of the obtained pale yellow oily substance, 1,1-carbonyldiimidazole (51 mg, 0.31 mmol), 1,8-diazabicyclo [5.4.0] Undec-7-ene (47 ⁇ L, 0.31 mmol) was added and stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 1 Using 2-amino-5-methoxypyrimidine instead of 2-amino-5-ethoxypyrimidine, the same reaction and treatment as in Step 1 of Example 11 was carried out to give 3-acetyl-4-hydroxy-1- ( 5-Methoxypyrimidin-2-yl) -6-methylpyridin-2 (1H) -one was obtained.
- Step 2 3-acetyl-4-hydroxy-1- (5 instead of 3-acetyl-1- (5-ethoxypyrimidin-2-yl) -4-hydroxy-6-methylpyridin-2 (1H) -one 4-Methoxypyrimidin-2-yl) -6-methylpyridin-2 (1H) -one was reacted and treated in the same manner as in Step 2 of Example 11 to give 4-hydroxy-1- (5-methoxypyrimidin-2 -Yl) -6-methylpyridin-2 (1H) -one was obtained.
- Step 3 4-hydroxy-1- (5-methoxypyrimidin-2-yl) instead of 1- (5-ethoxypyrimidin-2-yl) -4-hydroxy-6-methylpyridin-2 (1H) -one Using 6-methylpyridin-2 (1H) -one, the reaction and treatment were carried out in the same manner as in Step 3 of Example 11 to obtain 4 ′- ⁇ [4-hydroxy-1- (5-methoxypyrimidin-2-yl). -6-Methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbonitrile was obtained.
- Step 4 4 ′- ⁇ [1- (5-Ethoxypyrimidin-2-yl) -4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbo Instead of nitrile, 4 ′- ⁇ [4-hydroxy-1- (5-methoxypyrimidin-2-yl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2- The reaction and treatment were carried out using carbonitrile in the same manner as in Step 4 of Example 11, and 4 ′- ⁇ [4-butyl-1- (5-methoxypyrimidin-2-yl) -6-methyl-2-oxo-1 , 2-Dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbonitrile was obtained.
- Step 5 4 ′- ⁇ [4-Butyl-1- (5-ethoxypyrimidin-2-yl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2-carbo 4 ′- ⁇ [4-Butyl-1- (5-methoxypyrimidin-2-yl) -6-methyl-2-oxo-1,2-dihydropyridin-3-yl] methyl ⁇ biphenyl-2- instead of nitrile Reaction was carried out using carbonitrile in the same manner as in Step 5 of Example 11, and 3- ⁇ [2 ′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl ⁇ -4-butyl-1- (Methoxypyrimidin-2-yl) -6-methylpyridin-2 (1H) -one was obtained.
- Step 1 A solution of 4-hydroxy-6-methyl-2-pyrone (1.3 g, 10 mmol) in N, N-dimethylformamide (10 mL) at room temperature with sodium hydride (87 mg, 20 mmol), 4′-bromomethyl-2 -Cyanobiphenyl (2.7 g, 10 mmol) was added, and the mixture was stirred at 70 ° C overnight. Water was added and extracted with chloroform. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 2 4 ′-[(4-Hydroxy-6-methyl-2-oxo-2H-pyran-3-yl) methyl] biphenyl-2-carbonitrile (55 mg, 0.17 mmol) in dichloromethane (1.5 mL) To the solution were added pyridine (45 mg, 0.57 mmol) and trifluoromethanesulfonic anhydride (87 ⁇ L, 0.52 mmol) at room temperature, and the mixture was stirred at room temperature for 2 hours. Water was added and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 3 Trimethylaluminum (2 mol / L heptane solution, 0.22 mL, 0.44 mmol) was added to a solution of 2-aminopyridine (25 mg, 0.27 mmol) in 1,2-dichloroethane (3 mL) at room temperature under an argon atmosphere. The mixture was stirred at the same temperature for 1 hour. 4 ′-[(4-Butyl-6-methyl-2-oxo-2H-pyran-3-yl) methyl] biphenyl-2-carbonitrile (32 mg, 0.090 mmol) in 1,2-dichloroethane solution (2 mL) was added dropwise at room temperature and heated to reflux for 16 hours.
- Step 4 4 ′- ⁇ 4-Butyl-6-methyl-2-oxo-1- (pyridin-2-yl) -1,2-dihydropyridin-3-yl ⁇ methyl ⁇ biphenyl-2-carbonitrile (14 mg , 0.032 mmol) in toluene (1.5 mL) were added trimethylsilyl azide (211 ⁇ L, 1.61 mmol) and dibutyltin oxide (4.0 mg, 0.016 mmol), and the mixture was heated to reflux for 16 hours under an argon atmosphere.
- Step 1 Sodium hydrogen carbonate (378 mg, 4.5 mmol) was added to a dimethyl sulfoxide solution (3 mL) of hydroxylamine hydrochloride (260 mg, 3.8 mmol), and the mixture was stirred at 40 ° C. for 1 hour.
- 4 ′- ⁇ 4-butyl-6-methyl-2-oxo-1- (pyridin-2-yl) -1,2-dihydropyridin-3-yl ⁇ methyl obtained in Step 3 of Example 15 was used.
- a solution of biphenyl-2-carbonitrile 65 mg, 0.15 mmol
- dimethyl sulfoxide (2 mL) was added and stirred at 90 ° C. for 16 hours.
- Step 2 To a solution of the obtained pale yellow oil in N, N-dimethylformamide (2 mL), 1,1′-carbonyldiimidazole (61 mg, 0.38 mmol), 1,8-diazabicyclo [5.4.0] Undec-7-ene (56 ⁇ L, 0.38 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step 1 4 ′-[(1-Benzyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbohydrate obtained in Step 2 of Example 1
- nitrile 105 mg, 0.3 mmol
- N-dimethylformamide 3 mL
- sodium hydride 34 mg, 0.8 mmol
- 1-iodopropane 75 ⁇ L, 0.8 mmol
- Step 2 of 4 ′-[(1-Benzyl-6-methyl-2-oxo-4-propoxy-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbonitrile (50 mg, 0.11 mmol) Trimethylsilyl azide (730 ⁇ L, 5.6 mmol) and dibutyltin oxide (14 mg, 0.056 mmol) were added to a toluene (3 mL) solution, and the mixture was heated to reflux for 16 hours under an argon atmosphere.
- Step 1 Sodium hydrogen carbonate (427 mg, 5.1 mmol) was added to a dimethyl sulfoxide solution (3 mL) of hydroxylamine hydrochloride (294 mg, 4.2 mmol), and the mixture was stirred at 40 ° C. for 1 hour. 4 ′-[(1-Benzyl-6-methyl-2-oxo-4-propoxy-1,2-dihydropyridin-3-yl) methyl] biphenyl-2-carbohydrate obtained in Step 1 of Example 17 was added to the reaction solution. A dimethyl sulfoxide solution (2 mL) of nitrile (76 mg, 0.17 mmol) was added and stirred at 90 ° C. for 16 hours.
- Step 2 To a N, N-dimethylformamide solution (2 mL) of the obtained pale yellow oily substance, 1,1′-carbonyldiimidazole (69 mg, 0.42 mmol), 1,8-diazabicyclo [5.4.0] Undec-7-ene (63 ⁇ L, 0.42 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution and extracted with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Test Example 1 Angiotensin II antagonistic action in isolated rabbit blood vessels
- the antagonistic action of the compound of the present invention on angiotensin II type 1 receptor was calculated from a dose-response curve for angiotensin II-induced vasoconstriction using a rabbit isolated blood vessel specimen.
- a thoracic aortic ring specimen of a rabbit (New Zealand White: male, 2.4-3.0 kg) was prepared from Krebs-Henseleite solution (composition: 118 mM NaCl, 4.7 mM KCl, 2.55 mM CaCl 2 , 1.18 mM MgSO 4).
- the angiotensin II contraction reaction was converted into a relative value (%) relative to the angiotensin II (10 nM) contraction in the absence of each Example compound, and the statistical analysis program, SAS preclinical package Ver 5.0 ( SAS institute Japan Co., Tokyo) was used to calculate 50% inhibitory concentration (IC 50 value).
- the compounds described in the Examples have angiotensin II inhibitory activity at a concentration of 10 ⁇ M.
- the inhibitory activities (IC 50 values) of these compounds are shown in Table 1. As can be seen from Table 1, the compounds of the present invention had strong angiotensin II antagonism.
- Test Example 2 PPAR ⁇ Activating Activity
- COS7 cells DS Pharma Biomedical, Osaka
- COS7 cells in culture was performed in a CO 2 concentration of 5% in the culture solution using a DMEM medium containing 10% fetal bovine serum, glutamic acid and antibiotics.
- the expression vector is a chimera in which the DNA binding region of Gal4, a yeast transcription factor, and the ligand binding region of human PPAR ⁇ 2, ie, amino acids 1 to 147 of Gal4 transcription factor and 182 to 505 of human PPAR ⁇ 2. A fusion of these amino acids was used.
- luciferase containing 5 Gal4 recognition sequences in the promoter region was used as a reporter vector. Plasmid transfection into cells was performed by a method using jetPEI (Funakoshi, Tokyo). Furthermore, an expression vector for ⁇ -galactosidase was used as an internal standard. After transfection into the cells, the medium was replaced with a DMEM medium (containing 1% serum) to which a test compound was added, and further cultured for 16 hours. Thereafter, luciferase activity and ⁇ -galactosidase activity in the cell lysate were measured.
- DMEM medium containing 1% serum
- DMSO dimethyl sulfoxide
- the compound represented by the general formula (1) of the present invention has both a strong angiotensin II receptor antagonistic action and a PPAR ⁇ activation action. Therefore, the compound (1) represented by the general formula (1) of the present invention and a pharmaceutically acceptable salt thereof are diseases involving angiotensin II and PPAR ⁇ , such as hypertension, heart disease, angina pectoris, Cerebrovascular disorder, cerebral circulatory disorder, ischemic peripheral circulatory disorder, renal disease, arteriosclerosis, inflammatory disease, type 2 diabetes, diabetic complication, insulin resistance syndrome, syndrome X, metabolic syndrome, hyperinsulinemia, It was found that it can be suitably used as an active ingredient for the prevention and / or treatment of diseases such as
- the 2-pyridone derivative represented by the general formula (1) of the present invention, or a salt thereof, or a solvate thereof provides a novel compound having both an angiotensin II receptor antagonistic action and a PPAR ⁇ activation action.
- Diseases involving angiotensin II and PPAR ⁇ such as hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disorder, ischemic peripheral circulatory disorder, renal disease, arteriosclerosis, inflammatory disease, type 2 diabetes, It becomes an active ingredient of a novel drug useful as a preventive and / or therapeutic agent for diseases such as diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome, hyperinsulinemia, etc., and has industrial applicability. is doing.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
一方、特許文献6には、次式(B):
しかしながら当該文献中の化合物は、薬理活性としてPPARγ活性化作用や糖尿病、肥満又はメタボリックシンドロームの治療に関する記載や示唆はない。また、R2にカルボキシル基、テトラゾリル基、トリフルオロメタンスルホン酸アミド基、リン酸基又はスルホン酸基等のプロトン放出性の置換基を有することを特徴としている点でも本発明の化合物と異なる。
また、特許文献7には、下式(C):
しかしながら当該文献中の化合物は、薬理活性としてPPARγ活性化作用や糖尿病、肥満又はメタボリックシンドロームの治療に関する記載や示唆はない。また、ピリジン環の窒素原子上に置換基を有しない点でも本発明の化合物と異なる。
[1] 次の一般式(1):
R2は、C1-6アルキル基又はC3-8シクロアルキル基を示し、
R3は、C1-6アルキル基、C6-10アリール-C1-6アルキル基、C1-6アルコキシ-C1-6アルキル基、又は次式(2):
R4は、次式(3)又は(4):
で表される化合物若しくはその塩、又はそれらの溶媒和物。
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-4-ブチル-6-メチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-4-ブチル-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロピルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロピル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-ペンチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-ペンチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-フェネチルピリジン-2(1H)-オン、
3-{4’-[(4-ブチル-6-メチル-2-オキソ-1-フェネチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(2-メトキシエチル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(2-メトキシエチル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-(ピリジン-2-イル)ピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-6-メチル-2-オキソ-1-(ピリジン-2-イル)-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロポキシピリジン-2(1H)-オン、
及び、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロポキシ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
からなる群から選ばれる化合物である、前記[1]に記載の化合物若しくはその塩、又はそれらの溶媒和物。
なお、上記化合物の命名におけるブチルなどのアルキル基は、特に指定されていない限り直鎖(ノルマル)のものを表している。
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-4-ブチル-6-メチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-4-ブチル-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロピルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロピル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-ペンチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-ペンチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-フェネチルピリジン-2(1H)-オン、
3-{4’-[(4-ブチル-6-メチル-2-オキソ-1-フェネチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(2-メトキシエチル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(2-メトキシエチル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-(ピリジン-2-イル)ピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-6-メチル-2-オキソ-1-(ピリジン-2-イル)-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロポキシピリジン-2(1H)-オン、
及び、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロポキシ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
からなる群から選ばれる化合物を挙げることができる。
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-フェネチルピリジン-2(1H)-オン、
3-{4’-[(4-ブチル-6-メチル-2-オキソ-1-フェネチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(2-メトキシエチル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(2-メトキシエチル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{4’-{[4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{4’-{[4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、及び、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-(ピリジン-2-イル)ピリジン-2(1H)-オン、
からなる群から選ばれる化合物を挙げることができる。
上記一般式(1)で表される化合物若しくはその塩、又はそれらの溶媒和物は種々の公知の方法で製造することができ、特に制限されるものではなく、例えば、次に説明する反応工程に従い製造することができる。また、下記反応を行う際において、反応部位以外の官能基については必要に応じて予め保護しておき、適当な段階においてこれを脱保護してもよい。保護、脱保護条件としては一般に用いられる方法(Protective Groups in Organic Synthesis Third Edition, John Wiley & Sons, Inc.)を参考にして行うことができる。さらに、各工程において、反応は通常行われる方法で行えばよく、単離精製は結晶化、再結晶化、クロマトグラフィー等の慣用される方法を適宜選択し、又は組み合わせて行えばよい。
本発明の一般式(1)で表される化合物のうち、R4がテトラゾリル基である化合物(1a)は、ニトリル誘導体(5)にアジド化合物を反応させることにより製造することができる。また、R4が5-オキソ-1,2,4-オキサジアゾリル基である化合物(1b)は、ニトリル誘導体(5)とヒドロキシルアミンを反応させてアミドオキシム体(6)とし、次いで、アミドオキシム体(6)とカルボニル試薬を反応させることにより製造することができる。この反応経路を化学反応式で示すと次の通りである。
[反応経路図1]
R1がアルキル基である一般式(5)で表される化合物は、2-ピロン誘導体(7)とアミン誘導体(8)を反応して2-ピリドン誘導体(9)とし、得られた化合物(9)と化合物(10)を反応して化合物(11)とし、得られた化合物(11)の水酸基を脱離基に変換して化合物(12)とし、化合物(12)と有機亜鉛試薬(13)を触媒存在下反応することにより製造することができる。この反応経路を化学反応式で示すと次の通りである。
[反応経路図2]
水酸基からスルホニルオキシ基の変換は、例えば、化合物(11)を、スルホン酸無水物又はスルホン酸ハライドと溶媒中、塩基の存在下で反応させればよい。溶媒としては、例えばジクロロメタン、クロロホルム、ジエチルエーテル、テトラヒドロフラン、ジオキサン、ベンゼン、トルエン、キシレン、酢酸エチル、アセトニトリル、プロピオニトリル、N,N-ジメチルホルムアミド等を単独又は組み合わせて使用することができる。スルホン酸無水物としては、メタンスルホン酸無水物、ベンゼンスルホン酸無水物、トリフルオロメタンスルホン酸無水物等が挙げられ、スルホン酸ハライドとしては、メタンスルホン酸クロリド、p-トルエンスルホン酸クロリド等が挙げられる。塩基としては例えばピリジン、トリエチルアミン、N,N-ジイソプロピルエチルアミン等の有機塩基類、炭酸水素カリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸ナトリウム、炭酸カルシウム等の無機塩基類が挙げられる。反応条件は、使用する原料によって異なるが、-80~180℃、好ましくは0~100℃にて1分~3日間、好ましくは30分~24時間反応させることによって、X2がスルホニルオキシ基である化合物(12)が得られる。
[反応経路図3]
R1がアルキル基である一般式(5)で表される化合物は、2-ピロン誘導体(7)と化合物(10)を反応して、化合物(16)とし、得られた化合物(16)の水酸基を脱離基に変換して化合物(17)とし、化合物(17)と有機亜鉛試薬(13)を触媒存在下反応して化合物(18)とし、化合物(18)とアミン誘導体(8)を反応することによっても製造することもできる。この反応経路を化学反応式で示すと次の通りである。
[反応経路図4]
R1がアルコキシ基である化合物(5’)は、前記工程5に従って製造できる化合物(11)と化合物(19)を、溶媒中、塩基の存在下で反応することによって製造することができる。この反応経路を化学反応式で示すと次の通りである。
[反応経路図5]
s:シングレット(singlet)
d:ダブレット(doublet)
t:トリプレット(triplet)
q:カルテット(quartet)
m:マルチプレット(multiplet)
br:ブロード(broad)
brs:ブロードシングレット(broad singlet)
J:カップリング定数(coupling constant)
Hz:ヘルツ(Hertz)
CDCl3:重クロロホルム
DMSO-d6:重ジメチルスルホキシド
1H-NMR:プロトン核磁気共鳴
2.25 (3H, s), 4.86 (2H, s), 5.82 (1H, d, J=3 Hz),
5.97 (1H, d, J=3 Hz), 7.08-7.14 (2H, m), 7.21-7.35 (3H, m).
2.25 (3H, s), 3.94 (2H, s), 5.36 (2H, s),
6.04 (1H, s), 7.05-7.34 (5H, m), 7.41-7.58 (6H, m),
7.70 (1H, dt, J=1, 8 Hz), 7.79 (1H, dt, J=1, 8 Hz).
0.91 (3H, t, J=7 Hz), 1.32-1.42 (2H, m), 1.44-1.54 (2H, m),
2.26 (3H, s), 2.51 (2H, t, J=8 Hz), 4.07 (2H, s),
5.35 (2H, s), 5.95 (1H, s), 7.14 (2H, d, J=7 Hz),
7.21-7.34 (3H, m), 7.36-7.51 (6H, m),
7.60 (1H, dt, J=1, 8 Hz ), 7.73 (1H, dt, J=1, 8 Hz).
0.90 (3H, t, J=7 Hz), 1.30-1.40 (2H, m), 1.45-1.55 (2H, m),
2.23 (3H, s), 2.48 (2H, t, J=8 Hz), 3.85 (2H, s),
5.18 (2H, s), 6.01 (1H, s), 6.90 (2H, d, J=8 Hz),
6.95 (2H, d, J=8 Hz), 7.00 (2H, d, J=7 Hz),
7.17-7.52 (6H, m), 7.88 (1H, d, J= 8 Hz).
0.91 (3H, t, J=7 Hz), 1.31-1.41 (2H, m), 1.46-1.56 (2H, m),
2.22 (3H, s), 2.51 (2H, t, J=8 Hz), 3.89 (2H, s),
5.16 (2H, s), 6.00 (1H, s), 6.98 (2H, d, J=7 Hz),
7.08-7.18 (4H, m), 7.19-7.41 (5H, m),
7.51 (1H, dt, J=1, 8 Hz), 7.88 (1H, d, J= 8 Hz).
0.96 (3H, t, J=7 Hz), 1.48-1.61 (2H, m), 2.25 (3H, s),
2.50 (2H, t, J=8 Hz), 4.08 (2H, s), 5.35 (2H, s),
5.95 (1H, s), 7.05 (2H, d, J=7 Hz), 7.20-7.34 (3H, m),
7.36-7.50 (6H, m), 7.60 (1H, dt, J=1, 8 Hz),
7.72 (1H, dt, J=1, 8 Hz).
0.95 (3H, t, J=7 Hz), 1.49-1.61 (2H, m), 2.23 (3H, s),
2.47 (2H, t, J=8 Hz), 3.85 (2H, s), 5.18 (2H, s),
6.02 (1H, s), 6.88-6.96 (3H, m), 7.00 (2H, d, J=7 Hz),
7.19-7.51 (7H, m), 7.93 (1H, d, J= 7 Hz).
0.88 (3H, t, J=7 Hz), 1.28-1.37 (4H, m), 1.46-1.56 (2H, m),
2.25 (3H, s), 2.51 (2H, t, J=8 Hz), 4.07 (2H, s),
5.35 (2H, s), 5.95 (1H, s), 7.14 (2H, d, J=8 Hz),
7.20-7.33 (3H, m), 7.35-7.50 (6H, m),
7.60 (1H, dt, J=1, 8 Hz), 7.73 (1H, dt, J=1, 8 Hz).
0.88 (3H, t, J=7 Hz), 1.22-1.39 (4H, m), 1.50-1.64 (2H, m),
2.30 (3H, s), 2.56 (2H, t, J=8 Hz), 3.98 (2H, s),
5.32 (2H, s), 6.11 (1H, s), 6.97-7.11 (3H, m),
7.16-7.56 (7H, m), 7.76-7.86 (1H, m), 7.66-8.11 (2H, m).
2.11 (3H, s), 2.96 (2H, t, J=7 Hz), 4.16 (2H, t, J=7 Hz),
5.77 (1H, d, J=3 Hz), 5.84 (1H, d, J=3 Hz),7.16-7.30(5H,m).
2.15 (3H, s), 2.98 (2H, t, J=8 Hz), 3.93 (2H, s),
4.19 (2H, t, J=8 Hz), 5.91 (1H, s), 7.14-7.31 (5H, m),
7.39-7.88 (8H, m).
0.90 (3H, t, J=7 Hz), 1.30-1.40 (2H, m), 1.42-1.51 (2H, m),
2.19 (3H, s), 2.48 (2H, t, J=8 Hz), 3.02 (2H, t, J=8 Hz),
4.07 (2H, s), 4.21 (2H, t, J=8 Hz), 5.88 (1H, s),
7.19-7.32 (5H, m), 7.34-7.41 (3H, m), 7.43-7.49 (3H, m),
7.59 (1H, dt, J=1, 8 Hz), 7.71 (1H, d, J= 8 Hz).
0.88 (3H, t, J=7 Hz), 1.32-1.39 (2H, m), 1.40-1.46 (2H, m),
2.08 (3H, s), 2.43 (2H, t, J=8 Hz), 2.87 (2H, t, J=8 Hz),
3.84 (2H, s), 4.08 (2H, t, J=8 Hz), 5.93 (1H, s),
6.92 (4H, brs), 7.03-7.09 (2H, m), 7.15-7.23 (2H, m),
7.27-7.49 (4H, m), 7.86 (1H, d, J= 7 Hz).
0.93 (3H, t, J=7 Hz), 1.33-1.47 (4H, m), 2.19 (3H, s),
2.52 (2H, t, J=8 Hz), 2.96 (2H, t, J=8 Hz), 3.96 (2H, s),
4.14 (2H, t, J=8 Hz), 5.95 (1H, s), 7.14-7.31 (9H, m),
7.38-7.49 (2H, m), 7.54-7.62 (1H, m), 7.79 (1H, d, J= 8 Hz).
0.88 (3H, t, J=7 Hz), 1.28-1.39 (2H, m), 1.42-1.52 (2H, m),
2.35 (3H, s), 2.43 (2H, t, J=8 Hz), 3.16 (3H, s),
3.47 (2H, brs), 3.80 (2H, s), 4.04 (2H, brs), 5.99 (1H, s),
6.89 (4H, brs), 7.29-7.46 (3H, m), 7.87 (1H, d, J=7 Hz).
0.90 (3H, t, J=7 Hz), 1.31-1.40 (2H, m), 1.42-1.53 (2H, m),
2.40 (3H, s), 2.48 (2H, t, J=8 Hz), 3.31 (3H, s),
3.69 (2H, t, J=5 Hz), 4.02 (2H, s), 4.20 (2H, t, J=5 Hz),
5.92 (1H, s), 7.32-7.49 (6H, m), 7.60 (1H, dt, J=1, 8 Hz),
7.72 (1H, dd, J=1, 8 Hz).
0.90 (3H, t, J=7 Hz), 1.31-1.40 (2H, m), 1.42-1.53 (2H, m),
2.40 (3H, s), 2.48 (2H, t, J=8 Hz), 3.31 (3H, s),
3.69 (2H, t, J=5 Hz), 4.02 (2H, s), 4.20 (2H, t, J=5 Hz),
5.92 (1H, s), 7.32-7.49 (6H, m),
7.60 (1H, dt, J=1, 8 Hz), 7.72 (1H, dd, J=1, 8 Hz).
0.88 (3H, t, J=7 Hz), 1.28-1.39 (2H, m), 1.42-1.52 (2H, m),
2.35 (3H, s), 2.43 (2H, t, J=8 Hz), 3.16 (3H, s),
3.47 (2H, brs), 3.80 (2H, s), 4.04 (2H, brs), 5.99 (1H, s),
6.89 (4H, brs), 7.29-7.46 (3H, m), 7.87 (1H, d, J=7 Hz).
0.92 (3H, t, J=7 Hz), 1.33-1.43 (2H, m),
1.46-1.56 (2H, m), 2.40 (3H, s), 2.51 (2H, t, J=8 Hz),
3.27 (3H, s), 3.57 (2H, t, J=5 Hz), 3.89 (2H, s),
4.09 (2H, t, J=5 Hz), 5.99 (1H, s), 7.15 (2H, d, J=8 Hz),
7.18 (2H, d, J=8 Hz), 7.38-7.46 (2H, m),
7.56 (1H, t, J=8 Hz), 7.76 (1H, d, J=8 Hz).
1.51 (3H, t, J=7 Hz), 1.99 (3H, s), 2.68 (3H, s),
4.22 (2H, t, J=7 Hz), 5.93 (1H, s), 8.52 (2H, s).
1.48 (3H, t, J=7 Hz), 1.93 (3H, s), 4.29 (2H, t, J=7 Hz),
5.75 (1H, d, J=2 Hz), 6.03 (1H, d, J=2 Hz), 8.61 (2H, s).
1.43 (3H, t, J=7 Hz), 1.85 (3H, s), 3.90 (2H, s),
4.09 (2H, q, J=7 Hz), 5.91 (1H, s), 7.35-7.48 (6H, m),
7.58 (1H, dt, J=1, 8 Hz), 7.71 (1H, dd, J=1, 8 Hz),
8.42 (2H, s).
0.92 (3H, t, J=7 Hz), 1.33-1.42 (2H, m), 1.45-1.54 (5H, m),
1.97 (3H, s), 2.55 (2H, t, J=8 Hz), 4.02 (2H, s),
4.20 (2H, q, J=7 Hz), 6.00 (1H, s), 7.35-7.48 (6H, m),
7.60 (1H, dt, J=1, 8 Hz), 7.73 (1H, dd, J=1, 8 Hz),
8.51 (2H, s).
0.93 (3H, t, J=7 Hz), 1.35-1.60 (7H, m), 1.96 (3H, s),
2.58 (2H, t, J=8 Hz), 3.89 (2H, s), 4.16 (2H, q, J=7 Hz),
6.07 (1H, s), 7.02 (2H, d, J=8 Hz), 7.16 (2H, d, J=8 Hz),
7.34-7.57 (3H, m), 8.06 (1H, d, J=7 Hz), 8.43 (2H, s).
0.94 (3H, t, J=7 Hz), 1.35-1.45 (2H, m),
1.48 (3H, t, J=7 Hz), 1.50-1.59 (2H, m), 1.96 (3H, s),
2.58 (2H, t, J=8 Hz), 3.94 (2H, s), 4.18 (2H, q, J=7 Hz),
6.04 (1H, s), 7.16 (2H, d, J=8 Hz), 7.27 (2H, d, J=8 Hz),
7.35-7.45 (2H, m), 7.55 (1H, t, J=8 Hz),
7.73 (1H, d, J=8 Hz), 8.47 (2H, s).
1.99 (3H, s), 2.68 (3H, s), 4.01 (3H, s), 5.94 (1H, s),
8.55 (2H, s).
1.93 (3H, s), 4.03 (3H, s), 5.76 (1H, d, J=2 Hz),
6.04 (1H, d, J=2 Hz), 8.64 (2H, s).
1.83 (3H, s), 3.84 (3H, s), 3.88 (2H, s), 5.92 (1H, s),
7.34-7.48 (6H, m), 7.58 (1H, dt, J=1, 8 Hz),
7.71 (1H, d, J=8 Hz), 8.42 (2H, s).
0.92 (3H, t, J=7 Hz), 1.33-1.43 (2H, m), 1.44-1.54 (2H, m),
1.97 (3H, s), 2.55 (2H, t, J=8 Hz), 3.97 (3H, s),
4.02 (2H, s), 6.00 (1H, s), 7.35-7.48 (6H, m),
7.60 (1H, dt, J=1, 8 Hz), 7.73 (1H, dd, J=1, 8 Hz),
8.53 (2H, s).
0.92 (3H, t, J=7 Hz), 1.33-1.46 (2H, m), 1.49-1.59 (2H, m),
1.90 (3H, s), 2.54 (2H, t, J=8 Hz), 3.72 (3H, s),
3.84 (2H, s), 6.08 (1H, s), 6.96 (2H, d, J=8 Hz),
7.01 (2H, d, J=8 Hz), 7.31-7.46 (3H, m),
7.93 (1H, d, J=7 Hz), 8.34 (2H, s).
0.94 (3H, t, J=7 Hz), 1.36-1.47 (2H, m), 1.51-1.61 (2H, m),
1.96 (3H, s), 2.59 (2H, t, J=8 Hz), 3.92 (2H, s),
3.95 (3H, s), 6.06 (1H, s), 7.16 (2H, d, J=8 Hz),
7.24 (2H, d, J=8 Hz), 7.35-7.44 (2H, m),
7.54 (1H, t, J=8 Hz), 7.76 (1H, d, J=8 Hz), 8.49 (2H, s).
2.18 (3H, s), 3.76 (2H, s), 5.97 (1H, s), 7.38-7.56 (6H, m),
7.69 (1H, dt, J=1, 8 Hz), 7.78 (1H, d, J=8 Hz).
0.90 (3H, t, J=7 Hz), 1.31-1.51 (4H, m), 2.23 (3H, s),
2.46 (2H, t, J=8 Hz), 3.92 (2H, s), 5.90 (1H, s),
7.35 (2H, d, J=8 Hz), 7.38-7.51 (4H, m),
7.62 (1H, dt, J=1, 8 Hz), 7.74 (1H, dd, J=1, 8 Hz).
0.93 (3H, t, J=7.2 Hz), 1.34-1.44 (2H, m), 1.46-1.56 (2H, m),
1.96 (3H, s), 2.56 (2H, t, J=7.8 Hz), 4.02 (2H, s),
6.03 (1H, s), 7.35-7.48 (8H, m),
7.60 (1H, dt, J=1.2, 7.7 Hz), 7.73 (1H, dd, J=1.2, 7.7 Hz),
7.88 (1H, dt, J=1.8, 7.7 Hz), 8.65 (1H, dd, J=1.8, 5.5 Hz).
0.91 (3H, t, J=7.2 Hz), 1.31-1.42 (2H, m),
1.47-1.57 (2H, m), 1.89 (3H, s), 2.50 (2H, t, J=7.8 Hz),
3.77 (2H, s), 6.10 (1H, s), 6.86 (4H, brs),
7.05-7.11 (1H, m), 7.16 (1H, d, J=7.8 Hz),
7.28-7.44 (3H, m), 7.57-7.68 (1H, m), 7.84 (1H, d, J=7.3 Hz),
7.84 (1H, d, J=7.3 Hz), 8.36 (1H, d, J=3.9 Hz).
0.96 (3H, t, J=7.2 Hz), 1.38-1.50 (2H, m),
1.55-1.65 (2H, m), 1.96 (3H, s), 2.62 (2H, t, J=7.8 Hz),
3.93 (2H, s), 6.12 (1H, s), 7.19 (2H, d, J=8.0 Hz),
7.24 (2H, d, J=8.0 Hz), 7.32-7.58 (5H, m),
7.79 (1H, d, J=7.6 Hz), 7.88 (1H, t, J=7.6 Hz),
8.59 (1H, d, J=3.9 Hz).
1.03 (3H, t, J=7 Hz), 1.73-1.88 (2H, m), 2.26 (3H, s),
3.98 (2H, t, J=6 Hz), 4.00 (2H, s), 5.35 (2H, s),
5.93 (1H, s), 7.09-7.54 (11H, m), 7.59 (1H, dt, J=1, 8 Hz),
7.73 (1H, dt, J=1, 8 Hz).
0.99 (3H, t, J=7 Hz), 1.74-1.85 (2H, m), 2.24 (3H, s),
3.81 (2H, s), 3.97 (2H, t, J=6 Hz), 5.17 (2H, s),
5.98 (1H, s), 6.90 (2H, d, J=8 Hz), 6.99 (2H, d, J=7 Hz),
7.09 (2H, d, J=8 Hz), 7.17-7.52 (6H, m),
7.82 (1H, d, J= 8 Hz).
1.04 (3H, t, J=7 Hz), 1.78-1.88 (2H, m), 2.24 (3H, s),
3.87 (2H, s), 3.99 (2H, t, J=6 Hz), 5.19 (2H, s),
5.96 (1H, s), 7.02 (2H, d, J=7 Hz), 7.17 (2H, d, J=8 Hz),
7.14-7.57 (8H, m), 7.67 (1H, d, J= 8 Hz).
本発明の化合物のアンジオテンシンIIタイプ1受容体に対する拮抗作用は、ウサギ摘出血管標本を用いてアンジオテンシンIIによる血管収縮反応に対する用量-反応曲線により算出した。即ち、ウサギ(New Zealand White:雄性,2.4~3.0kg)の胸部大動脈リング標本をKrebs-Henseleite液(組成:118mM NaCl,4.7mM KCl,2.55mM CaCl2,1.18mM MgSO4,1.18mM KH2PO4,24.88mM NaHCO3,11.1mM D-glucose)で充填したマグヌス槽に懸垂し、各実施例化合物の存在下(1nmol/L~10μmol/L)のアンジオテンシンII(10nM)収縮反応を得た。測定中はマグヌス槽内を37℃に保温し、十分な混合ガス(95% O2,5% CO2)で連続的に通気した。アンジオテンシンII収縮反応は、各実施例化合物非存在下のアンジオテンシンII(10nM)収縮に対する相対値(%)に換算し、得られた濃度-反応曲線より統計解析プログラム、SAS前臨床パッケージVer5.0(SAS institute Japan Co., 東京)を用いて50%阻害濃度(IC50値)を算出した。
本発明化合物のPPARγに対するアゴニスト活性は、アフリカミドリザルの腎由来細胞株であるCOS7細胞(DSファーマバイオメディカル、大阪)を用いたトランスフェクションアッセイ法により測定した。COS7細胞の培養は5%のCO2濃度で行い、培養液には10%のウシ胎児血清、グルタミン酸及び抗生物質を含有するDMEM培地を用いた。
発現ベクターとしては、酵母の転写因子であるGal4のDNA結合領域と、ヒトPPARγ2のリガンド結合領域を融合したキメラ体、即ち、Gal4転写因子の1から147番目のアミノ酸及びヒトPPARγ2の182から505番目のアミノ酸を融合したものを用いた。また、レポーターベクターとして、プロモーター領域に5個のGal4認識配列が含まれているホタルルシフェラーゼを用いた。細胞へのプラスミドのトランスフェクションはjetPEI(フナコシ、東京)を用いた方法により行った。更にβ-ガラクトシダーゼの発現ベクターを内部標準として用いた。
細胞へのトランスフェクションの後、被検化合物を添加したDMEM培地(1%血清含有)に交換し、更に16時間の培養を行った。その後、細胞溶解液中のルシフェラーゼ活性及びβ-ガラクトシダーゼ活性を測定した。
なお、本実験では被検化合物の溶解・希釈にはジメチルスルホキシド(DMSO)を用い、細胞への処理の際はDMEM培地(1%血清含有)中のDMSO濃度が0.1%になるように調整した。各被検化合物の50%効果濃度(EC50、50% effect concentration)は統計解析プログラム、SAS前臨床パッケージVer5.0(SAS institute Japan Co., 東京)を用いて算出した。
Claims (13)
- 一般式(1)で表される化合物が、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-4-ブチル-6-メチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-4-ブチル-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロピルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロピル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-ペンチルピリジン-2(1H)-オン、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-ペンチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-フェネチルピリジン-2(1H)-オン、
3-{4’-[(4-ブチル-6-メチル-2-オキソ-1-フェネチル-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(2-メトキシエチル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(2-メトキシエチル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-エトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチルピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-1-(5-メトキシピリミジン-2-イル)-6-メチル-2-オキソ-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-4-ブチル-6-メチル-1-(ピリジン-2-イル)ピリジン-2(1H)-オン、
3-{4’-{[4-ブチル-6-メチル-2-オキソ-1-(ピリジン-2-イル)-1,2-ジヒドロピリジン-3-イル]メチル}ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
3-{[2’-(1H-テトラゾール-5-イル)ビフェニル-4-イル]メチル}-1-ベンジル-6-メチル-4-プロポキシピリジン-2(1H)-オン、
及び、
3-{4’-[(1-ベンジル-6-メチル-2-オキソ-4-プロポキシ-1,2-ジヒドロピリジン-3-イル)メチル]ビフェニル-2-イル}-1,2,4-オキサジアゾール-5(4H)-オン、
からなる群から選ばれる化合物である、請求項1に記載の化合物若しくはその塩、又はそれらの溶媒和物。 - 請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物、及び製薬上許容される担体を含有してなる医薬組成物。
- 請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物を有効成分とする、アンジオテンシンII受容体拮抗作用及びPPARγ活性化作用を併せ持つ医薬組成物。
- 請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物を有効成分とする循環器系疾患の予防及び/又は治療剤。
- 循環器系疾患が、高血圧症、心疾患、狭心症、脳血管障害、脳循環障害、虚血性末梢循環障害、腎疾患又は動脈硬化症である、請求項5に記載の予防及び/又は治療剤。
- 請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物を有効成分とする代謝性疾患の予防及び/又は治療剤。
- 代謝性疾患が、2型糖尿病、糖尿病網膜症、糖尿病性神経障害、糖尿病性腎症、インスリン抵抗性症候群、メタボリックシンドローム又は高インスリン血症である、請求項7に記載の予防及び/又は治療剤。
- 治療を必要としている患者に、請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物の有効量を投与することを特徴とする循環器系疾患の予防及び/又は治療方法。
- 治療を必要としている患者に、請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物の有効量を投与することを特徴とする代謝性疾患の予防及び/又は治療方法。
- 循環器系疾患の予防及び/又は治療のための製剤を製造するための、請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物の使用。
- 代謝性疾患の予防及び/又は治療のための製剤を製造するための、請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物の使用。
- アンジオテンシンII受容体拮抗作用及びPPARγ活性化作用の両方の作用を併せ持つ予防及び/又は治療剤としての請求項1又は2に記載の化合物若しくはその塩、又はそれらの溶媒和物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011547301A JPWO2011077711A1 (ja) | 2009-12-22 | 2010-12-22 | 新規な2−ピリドン誘導体及びこれを含有する医薬 |
US13/509,130 US20120225896A1 (en) | 2009-12-22 | 2010-12-22 | Novel 2-pyridone derivative and pharmaceutical product containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009290149 | 2009-12-22 | ||
JP2009-290149 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011077711A1 true WO2011077711A1 (ja) | 2011-06-30 |
Family
ID=44195264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/007417 WO2011077711A1 (ja) | 2009-12-22 | 2010-12-22 | 新規な2-ピリドン誘導体及びこれを含有する医薬 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120225896A1 (ja) |
JP (1) | JPWO2011077711A1 (ja) |
WO (1) | WO2011077711A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310696A (ja) * | 1992-05-06 | 1993-11-22 | Kotobuki Seiyaku Kk | ピリジン誘導体及びその製造法並びにこれを含有する薬剤 |
JPH07330760A (ja) * | 1993-05-06 | 1995-12-19 | Bayer Ag | 置換されたピリジン類および2−オキソ−1,2−ジヒドロピリジン類 |
JP2005501815A (ja) * | 2001-05-14 | 2005-01-20 | メルク エンド カムパニー インコーポレーテッド | 治療方法 |
WO2008062905A2 (en) * | 2006-11-24 | 2008-05-29 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2010095462A1 (ja) * | 2009-02-23 | 2010-08-26 | 興和株式会社 | 新規な3-(5-アルコキシピリミジン-2-イル)ピリミジン-4(3h)-オン構造を有する化合物及びこれを含有する医薬 |
-
2010
- 2010-12-22 JP JP2011547301A patent/JPWO2011077711A1/ja active Pending
- 2010-12-22 WO PCT/JP2010/007417 patent/WO2011077711A1/ja active Application Filing
- 2010-12-22 US US13/509,130 patent/US20120225896A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310696A (ja) * | 1992-05-06 | 1993-11-22 | Kotobuki Seiyaku Kk | ピリジン誘導体及びその製造法並びにこれを含有する薬剤 |
JPH07330760A (ja) * | 1993-05-06 | 1995-12-19 | Bayer Ag | 置換されたピリジン類および2−オキソ−1,2−ジヒドロピリジン類 |
JP2005501815A (ja) * | 2001-05-14 | 2005-01-20 | メルク エンド カムパニー インコーポレーテッド | 治療方法 |
WO2008062905A2 (en) * | 2006-11-24 | 2008-05-29 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2010095462A1 (ja) * | 2009-02-23 | 2010-08-26 | 興和株式会社 | 新規な3-(5-アルコキシピリミジン-2-イル)ピリミジン-4(3h)-オン構造を有する化合物及びこれを含有する医薬 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011077711A1 (ja) | 2013-05-02 |
US20120225896A1 (en) | 2012-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011077711A1 (ja) | 新規な2-ピリドン誘導体及びこれを含有する医薬 | |
DK2687523T3 (en) | New phenylpyridinderivat and pharmaceutical containing this | |
WO2010095462A1 (ja) | 新規な3-(5-アルコキシピリミジン-2-イル)ピリミジン-4(3h)-オン構造を有する化合物及びこれを含有する医薬 | |
WO2011024468A1 (ja) | 新規なスルホンアミド誘導体及びこれを含有する医薬 | |
DK2484675T3 (en) | Novel phenylpyridinderivat and pharmaceutical comprehensive this | |
WO2011077712A1 (ja) | 新規な1-(ビフェニル-4-イル-メチル)-1h-イミダゾール誘導体及びこれを含有する医薬 | |
JP2010180183A (ja) | 新規なピリミジン−4(3h)−オン構造を有する化合物及びこれを含有する医薬 | |
JP2012041309A (ja) | 新規な3−(5−エトキシピリミジン−2−イル)ピリミジン−4(3h)−オン構造を有する化合物及びこれを含有する医薬 | |
NZ616158B2 (en) | Novel phenylpyridine derivative and drug containing same | |
WO2011105099A1 (ja) | 新規な4-アルコキシピリミジン構造を有する化合物及びこれを含有する医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10838949 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011547301 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13509130 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10838949 Country of ref document: EP Kind code of ref document: A1 |